Article | Published:

TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell–mediated pathology

Nature Immunology volume 8, pages 13901397 (2007) | Download Citation

Abstract

Studies have shown that transforming growth factor-β (TGF-β) and interleukin 6 (IL-6) are required for the lineage commitment of pathogenic IL-17-producing T helper cells (TH-17 cells). Unexpectedly, here we found that stimulation of myelin-reactive T cells with TGF-β plus IL-6 completely abrogated their pathogenic function despite upregulation of IL-17 production. Cells stimulated with TGF-β plus IL-6 were present in the spleen as well as the central nervous system, but they failed to upregulate the proinflammatory chemokines crucial for central nervous system inflammation. In addition, these cells produced IL-10, which has potent anti-inflammatory activities. In contrast, stimulation with IL-23 promoted expression of IL-17 and proinflammatory chemokines but not IL-10. Hence, TGF-β and IL-6 'drive' initial lineage commitment but also 'restrain' the pathogenic potential of TH-17 cells. Our findings suggest that full acquisition of pathogenic function by effector TH-17 cells is mediated by IL-23 rather than by TGF-β and IL-6.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240 (2005).

  2. 2.

    et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006).

  3. 3.

    et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198, 1951–1957 (2003).

  4. 4.

    et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121–1133 (2006).

  5. 5.

    et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203, 2271–2279 (2006).

  6. 6.

    , , , & Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910–1914 (2003).

  7. 7.

    , , , & TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179–189 (2006).

  8. 8.

    et al. Transforming growth factor-β induces development of the TH17 lineage. Nature 441, 231–234 (2006).

  9. 9.

    et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133–1141 (2005).

  10. 10.

    et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7, 929–936 (2006).

  11. 11.

    et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7, 937–945 (2006).

  12. 12.

    et al. IL-25 regulates Th17 function in autoimmune inflammation. J. Exp. Med. 204, 161–170 (2007).

  13. 13.

    et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26, 371–381 (2007).

  14. 14.

    et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317, 256–260 (2007).

  15. 15.

    , , & Signals mediated by transforming growth factor-β initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat. Immunol. 7, 1151–1156 (2006).

  16. 16.

    , , , & Mechanisms of recovery from experimental autoimmune encephalomyelitis: T cell deletion and immune deviation in myelin basic protein T cell receptor transgenic mice. J. Neuroimmunol. 82, 149–159 (1998).

  17. 17.

    et al. Oral administration of myelin induces antigen-specific TGF-β1-secreting T cells in multiple sclerosis patients. Ann. NY Acad. Sci. 815, 412–422 (1997).

  18. 18.

    , , , & Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265, 1237–1240 (1994).

  19. 19.

    et al. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. J. Immunol. 146, 3012–3017 (1991).

  20. 20.

    et al. Protective effect of transforming growth factor β1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. USA 88, 2918–2921 (1991).

  21. 21.

    et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8, 967–974 (2007).

  22. 22.

    et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 448, 484–487 (2007).

  23. 23.

    et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448, 480–483 (2007).

  24. 24.

    et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445, 648–651 (2007).

  25. 25.

    , , , & A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203, 1685–1691 (2006).

  26. 26.

    et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744–748 (2003).

  27. 27.

    , , & Chemokine expression in murine experimental allergic encephalomyelitis. J. Neuroimmunol. 58, 167–176 (1995).

  28. 28.

    , , , & Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 193, 713–726 (2001).

  29. 29.

    & Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J. Immunol. 161, 2667–2671 (1998).

  30. 30.

    et al. Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J. Neuroimmunol. 130, 10–21 (2002).

  31. 31.

    , , & CD4+CD25Foxp3 Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 204, 285–297 (2007).

  32. 32.

    et al. Conventional T-bet+Foxp3 Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J. Exp. Med. 204, 273–283 (2007).

  33. 33.

    et al. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol. 161, 3299–3306 (1998).

  34. 34.

    , , , & Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 189, 1005–1010 (1999).

  35. 35.

    & TGF-β, a 'double agent' in the immune pathology war. Nat. Immunol. 7, 557–559 (2006).

  36. 36.

    et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med. 203, 2485–2494 (2006).

  37. 37.

    et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203, 2473–2483 (2006).

  38. 38.

    et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25, 309–318 (2006).

  39. 39.

    , , , & IFN-γ plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157, 3223–3227 (1996).

  40. 40.

    , , & CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ TH-17 cells in relapsing EAE. Nat. Immunol. 8, 172–180 (2007).

  41. 41.

    & Epitope spreading. Curr. Opin. Immunol. 8, 831–836 (1996).

  42. 42.

    et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol (2007).

  43. 43.

    , , & TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J. Exp. Med. 201, 1061–1067 (2005).

  44. 44.

    et al. Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25– T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172, 5149–5153 (2004).

  45. 45.

    et al. Conversion of peripheral CD4+CD25 naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875–1886 (2003).

  46. 46.

    , & T cell-produced transforming growth factor-β1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 26, 579–591 (2007).

  47. 47.

    , & Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J. Immunol. 175, 3025–3032 (2005).

  48. 48.

    & Suppressor T cells in human diseases. J. Exp. Med. 200, 273–276 (2004).

  49. 49.

    , , & Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971–979 (2004).

  50. 50.

    et al. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109, 131–140 (2002).

  51. 51.

    Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531–562 (2004).

Download references

Acknowledgements

We thank B. Desai and S. Jungers for assistance with flow cytometry; J. Mattson for real-time PCR data; B. Joyce-Shaikh for technical assistance; and R. Kastelein for comments.

Author information

Affiliations

  1. Schering-Plough Biopharma, Palo Alto, California 94304, USA.

    • Mandy J McGeachy
    • , Kristian S Bak-Jensen
    • , Yi Chen
    • , Cristina M Tato
    • , Wendy Blumenschein
    • , Terrill McClanahan
    •  & Daniel J Cua

Authors

  1. Search for Mandy J McGeachy in:

  2. Search for Kristian S Bak-Jensen in:

  3. Search for Yi Chen in:

  4. Search for Cristina M Tato in:

  5. Search for Wendy Blumenschein in:

  6. Search for Terrill McClanahan in:

  7. Search for Daniel J Cua in:

Contributions

M.J.M. designed and did all experiments and prepared the manuscript; K.S.B.-J. assisted with in vitro experiments; Y.C. and C.M.T. assisted with in vivo experiments; W.B. and T.M. did quantitative PCR analysis; and D.J.C. did cerebroventricular injections, supervised the studies and preparation of the manuscript.

Competing interests

The authors are employed by or were previously employed by Schering-Plough Biopharma.

Corresponding author

Correspondence to Daniel J Cua.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–8

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ni1539

Further reading